Nektar’s Immuno-Oncology Clinical Trial Collaboration with Syndax

Nektar Therapeutics (NKTR) and Syndax Pharmaceuticals (SNDX) have entered a collaboration for the evaluation of the efficacy and safety of the combination therapy of Nektar’s CD122-biased agonist NKTR-214 and Syndax’s small molecule Class 1 specific HDAC inhibitor entinostat for the treatment of patients suffering from metastatic melanoma that have previously reported treatment progression with an anti-PD-1 (programmed death receptor-1) agent. The recently presented preclinical study results showed that the NKTR-214+entinostat combination therapy significantly inhibited tumor growth in kidney and colon cancers. The trial will focus on establishing the recommended dosage of the combination therapy in the Phase 1b stage.